- EMEA Innovative Medicine
- Our innovation
- Focus areas
- Oncology
- Multiple myeloma
Multiple myeloma
As multiple myeloma progresses, remissions become progressively shorter and relapses become more common with each line of therapy.[2][3] Treatments for multiple myeloma are more effective now than they have ever been, with a number of options available.[4][5] Despite the progress, multiple myeloma remains incurable, and after multiple relapses, patients start to run out of options. New and effective therapies are needed to extend and improve their lives.[2][3][6]
At Johnson & Johnson we are striving to change the trajectory of this disease and are uniquely positioned to provide multiple treatment options to patients, across all lines of therapy. We innovate with purpose to lead where medicine is going by applying cutting-edge technologies to reshape care – advancing the next wave of innovations and driving towards a cure.[7]
Multiple myeloma in numbers

Our legacy in multiple myeloma
Our legacy of delivering firsts is a testament to our ambition to get in front of cancer and we remain focused in areas of high unmet medical need such as multiple myeloma to transform care and deliver curative regimens.

Our goal: working towards a cure
We want to give people a chance to live longer, better lives free of their disease so they can focus on what’s important to them.
A multiple myeloma diagnosis is unique to each individual, which means we need more than just one option to face this complex disease. One simple breakthrough treatment isn’t enough when every patient is unique. That’s why we’re pursuing a portfolio of immunotherapies that target the disease from every angle, and at every stage. Curing multiple myeloma is our mission; we are prepared, and we are leading the way.

Our approach to shifting the treatment paradigm
With our commitment and expertise, we are confident in our ability to continue to deliver tailored treatment options for all patients with multiple myeloma, and ultimately we hope to enable physicians to treat to cure.

Our dedication to improving patient outcomes and experiences
In 2023, we partnered with an expert group of patient advocates, clinical leaders, researchers and policymakers, to establish the Multiple Myeloma Collaboration Council. The first output from this partnership was the Multiple Myeloma Call-to-Action which identified key areas of unmet need and suggested solutions on how to address them as we look to advance patient outcomes.[13]
Visit the J&J withMe® Multiple Myeloma site here
You are now leaving jnj.com/innovativemedicine/emea
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
More from oncology at Johnson & Johnson Innovative Medicine EMEA
References You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. You are now leaving jnj.com/innovativemedicine/emea This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
[1] Multiple Myeloma Research Foundation. Understanding Multiple Myeloma. Available at:
https://themmrf.org/multiple-myeloma/
[2] Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023;30(2):2322-2347.
[3] Hernández-Rivas JÁ, et al. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res. 2022;10(1):1-23. Multiple Myeloma Research Foundation. Understanding Multiple Myeloma. Available at:
https://themmrf.org/multiple-myeloma/
[4] Myeloma UK. Myeloma: an introduction. Available at:
https://www.myeloma.org.uk/wp-content/uploads/2023/10/Myeloma-UK-Myeloma-an-Introduction.pdf
[5] Myeloma Patients Europe. Multiple Myeloma – A Patients’ Guide. Available at:
https://www.mpeurope.org/wp-content/uploads/2021/02/Patients-guide-mpe-web-version-V2.pdf
[6] Podar K, Leleu X. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. Cancers (Basel). 2021;13(20):5154.
[7] Nature. Janssen Oncology—leading the way in transformational innovation. Available at:
https://www.nature.com/articles/d43747-022-00205-3
[8] ECIS - European Cancer Information System. Estimates of cancer incidence in 2022, by country. Multiple myeloma. Available at:
https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$4-1,2$3-51$6-0,85$5-2022,2022$7-7$2-All$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27
[9] ECIS - European Cancer Information System. Estimates of cancer mortality in 2022, by country. Multiple myeloma. Available at:
https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1,2$3-51$6-0,85$5-2022,2022$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27
[10] Gavriatopoulou M, et al. Metabolic Disorders in Multiple Myeloma. Int J Mol Sci. 2021;22(21):11430.
[11] American Cancer Society. Multiple myeloma: causes, risk factors, and prevention. Available at:
https://www.cancer.org/content/dam/CRC/PDF/Public/8739.00.pdf
[12] Cancer Research UK. Survival for myeloma. Available at:
https://www.cancerresearchuk.org/about-cancer/myeloma/survival
[13] The Multiple Myeloma Call-To-Action. Available at:
https://www.mmcalltoaction.com/pdf/MMDifference.pdf
CP-506094
March 2025